• 1
    Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Fay MP, Feuer EJ, Edwards BK, eds. SEER Cancer Statistics Review, 1975–2000. Bethesda, MD: National Cancer Institute. (last accessed 5 August 2005), 2003.
  • 2
    Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, Lower A, Grudzinskas JG, Oram D. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 1993; 306: 10304.
  • 3
    Partridge EE, Barnes MN. Epithelial ovarian cancer: prevention, diagnosis and treatment. CA Cancer J Clin 1999; 49: 297316.
  • 4
    Bonovas S, Filioussi K, Sitaras NM. Do non-steroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis. Br J Clin Pharmacol 2005; 60: 194203.
  • 5
    Greenland S. Invited commentary. Am J Epidemiol 1994; 140: 2906.
  • 6
    Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999; 282: 105460.
  • 7
    Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational studies in Epidemiology (MOOSE) Group. JAMA 2000; 283: 200812.
  • 8
    Hasselblad V, Eddy DM, Kotchmar DJ. Synthesis of environmental evidence. J Air Waste Manag Assoc 1992; 42: 66271.
  • 9
    Friedenreich CM, Brant RF, Riboli E. Influence of methodologic factors in a pooled analysis of 13 case–control studies of colorectal cancer and dietary fiber. Epidemiology 1994; 5: 667.
  • 10
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 71948.
  • 11
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 17788.
  • 12
    Petitti DB. Statistical methods in meta-analysis. In: Meta-Analysis, Decision Analysis and Cost-Effectiveness Analysis, ed. PetittiDB. New York: Oxford University Press 1994; 90114.
  • 13
    Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088101.
  • 14
    Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ 1997; 315: 62934.
  • 15
    Cochran WG. The combination of estimates from different experiments. Biometrics 1954; 8: 10129.
  • 16
    Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 55760.
  • 17
    Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Techn Bull 1999; 8: 157.
  • 18
    Moysich KB, Mettlin C, Natarajan N. Nonsteroidal anti-inflammatory drugs and ovarian cancer risk. Am J Epidemiol 1999; 149: 217.
  • 19
    Cramer DW, Titus-Ernstoff L, Harlow BL, Bohlke K, Greenberg ER. Acetaminophen use and ovarian cancer. Am J Epidemiol 1997; 145: 347.
  • 20
    Tzonou A, Polychronopoulou A, Hsieh CC, Rebelakos A, Karakatsani A, Trichopoulos D. Hair dyes, analgesics, tranquilizers and perineal talc application as risk factors for ovarian cancer. Int J Cancer 1993; 55: 40810.
  • 21
    Lipworth L, Friis S, Mellemkjaer L, Signorello LB, Johnsen SP, Nielsen GL, McLaughlin JK, Blot WJ, Olsen JH. A population-based cohort study of mortality among adults prescribed paracetamol in Denmark. J Clin Epidemiol 2003; 56: 796801.
  • 22
    Lacey JV Jr, Sherman ME, Hartge P, Schatzkin A, Schairer C. Medication use and risk of ovarian carcinoma: a prospective study. Int J Cancer 2004; 108: 2816.
  • 23
    Friis S, Nielsen GL, Mellemkjaer L, McLaughlin JK, Thulstrup AM, Blot WJ, Lipworth L, Vilstrup H, Olsen JH. Cancer risk in persons receiving prescriptions for paracetamol: a Danish cohort study. Int J Cancer 2002; 97: 96101.
  • 24
    Fairfield KM, Hunter DJ, Fuchs CS, Colditz GA, Hankinson SE. Aspirin, other NSAIDs, and ovarian cancer risk (United States). Cancer Causes Control 2002; 13: 53542.
  • 25
    Meier CR, Schmitz S, Jick H. Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 2002; 22: 3039.
  • 26
    Moysich KB, Mettlin C, Piver MS, Natarajan N, Menezes RJ, Swede H. Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10: 9036.
  • 27
    Rosenberg L, Palmer JR, Rao RS, Coogan PF, Strom BL, Zauber AG, Stolley PD, Shapiro S. A case–control study of analgesic use and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2000; 9: 9337.
  • 28
    Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greenberg ER. Over-the-counter analgesics and risk of ovarian cancer. Lancet 1998; 351: 1047.
  • 29
    Rodriguez C, Henley SJ, Calle EE, Thun MJ. Paracetamol and risk of ovarian cancer mortality in a prospective study of women in the USA. Lancet 1998; 352: 13545.
  • 30
    Signorello LB, McLaughlin JK, Lipworth L, Friis S, Sorensen HT, Blot WJ. Confounding by indication in epidemiologic studies of commonly used analgesics. Am J Ther 2002; 9: 199205.
  • 31
    Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in research. Lancet 1991; 337: 86772.
  • 32
    Simes JR. Publication bias: the case for an international registry of trials. J Clin Oncol 1986; 4: 152941.
  • 33
    Sterling TD. Publication decisions and their possible effects on inferences drawn from tests of significance—or vice versa. JASA 1959; 54: 304.
  • 34
    Psaty BM, Koepsell TD, Lin D, Weiss NS, Siscovick DS, Rosendaal FR, Pahor M, Furberg CD. Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc 1999; 47: 74954.
  • 35
    Mills GB. Mechanisms underlying chemoprevention of ovarian cancer. Clin Cancer Res 2002; 8: 710.
  • 36
    Altinoz MA, Korkmaz R. NF-kappaB, macrophage migration inhibitory factor and cyclooxygenase-inhibitions as likely mechanisms behind the acetaminophen- and NSAID-prevention of the ovarian cancer. Neoplasma 2004; 51: 23947.
  • 37
    National Toxicology Program. Toxicology and Carcinogenesis Studies of Acetaminophen (CAS No. 103-90-2) in F344/N Rats and B6C3F1 Mice (Feed Studies). Technical report series no. 394. NIH publication no. 92–3489. Research Triangle Park, NC: US Department of Health and Human Services, Public Health Service, National Institutes of Health 1993.
  • 38
    Cramer DW, Liberman RF, Hornstein MD, McShane P, Powers D, Li EY, Barbieri R. Basal hormone levels in women who use acetaminophen for menstrual pain. Fertil Steril 1998; 70: 3713.
  • 39
    Lawson JA, Fisher MA, Simmons CA, Farhood A, Jaeschke H. Inhibition of Fas receptor (CD95)-induced hepatic caspase activation and apoptosis by acetaminophen in mice. Toxicol Appl Pharmacol 1999; 156: 17986.
  • 40
    Senter PD, Al-Abed Y, Metz CN, Benigni F, Mitchell RA, Chesney J, Han J, Gartner CG, Nelson SD, Todaro GJ, Bucala R. Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc Natl Acad Sci USA 2002; 99: 1449.
  • 41
    Freedman AN, Seminara D, Gail MH, Hartge P, Colditz GA, Ballard-Barbash R, Pfeiffer RM. Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst 2005; 97: 71523.
  • 42
    Rosner BA, Colditz GA, Webb PM, Hankinson SE. Mathematical models of ovarian cancer incidence. Epidemiology 2005; 16: 50815.